OTC · NLBS
NutraLife BioSciences, Inc.
$0.00$0.00 (0.0%)
NutraLife BioSciences, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
Loading market information…
OTC · ACORQ · USD
Stock price, earnings
Quote as of Aug 19, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acorda Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acorda Therapeutics, Inc. operates as a biopharmaceutical enterprise focused on researching, developing, and bringing to market medical treatments for neurological conditions, predominantly in the United States. The company offers Ampyra (dalfampridine), an oral medication aimed at enhancing walking capabilities in adult patients experiencing multiple sclerosis. Furthermore, it sells Inbrija, an inhaled formulation of levodopa, which is prescribed for the temporary management of "OFF" episodes in individuals with Parkinson's disease who are already on a carbidopa/levodopa regimen. Ampyra is also distributed internationally as Fampyra across markets in Europe, Asia, and the Americas. Acorda also holds a partnership and licensing arrangement with Biogen Inc. regarding the development and commercialization of Ampyra. Established in 1995, the company's main office is situated in Pearl River, New York. A notable recent event is the filing of a voluntary petition for reorganization under Chapter 11 by Acorda Therapeutics, Inc. and its associated entities on April 1, 2024, in the U.S. Bankruptcy Court for the Southern District of New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:21 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.56-672.22% vs estimate |
| $31.05M+6.7% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
NutraLife BioSciences, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
New You, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Genesis Healthcare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.97% below the high.
$0.00$0.00 (0.0%)
Advanzeon Solutions, Inc.: Healthcare · Medical - Care Facilities.
$0.00$0.00 (0.0%)
MagForce AG: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Navidea Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
$0.00$0.00 (0.0%)
Nanomix Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Hempfusion Wellness Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
